Estimating the broader fiscal consequences of acute hepatic porphyria (AHP) with recurrent attacks in Belgium using a public economic analytic framework

Orphanet Journal of Rare Diseases

Julien Patris¹  Nikos Kotsopoulos²  Mark P. Connolly³  Sebastian Vermeersch⁴  David Cassiman⁵ 

[1] Alnylam Pharmaceuticals, Antonio Vivaldistraat 150, 1083 HP, Amsterdam, Netherlands;Global Market Access Solutions Sarl, St-Prex, Switzerland;Global Market Access Solutions Sarl, St-Prex, Switzerland;Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, 9713 AV, Groningen, The Netherlands;HICT, Ottergemsesteenweg-Zuid 808 B/354, 9000, Ghent, Belgium;Metabolic Center, Department of Gastroenterology-Hepatology, University of Leuven, Leuven, Belgium;

关键词: Acute hepatic porphyria (AHP);    Disability;    Public economics;    Cost-analysis;    Taxation;    Public benefits;    Employment;    Fiscal analysis;   

DOI  :  10.1186/s13023-021-01966-3

来源: Springer

【 授权许可】

CC BY